BRIEF RESEARCH REPORT article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1620764
This article is part of the Research TopicOrganoids for Drug DiscoveryView all 10 articles
Patient-Derived Organoids reveal marked heterogeneity in chemosensitivity profiles of colorectal cancer and a potential association with HER2 Status
Provisionally accepted
- 1Department of Clinical Laboratory, Second People's Hospital of Jiangyou, Mianyang, China
- 2Department of Oncology, Second People's Hospital of Jiangyou, Mianyang, China
- 3Chengdu Tianfu Organoid Biobank Co., LTD, Chengdu, China
- 4Department of Translational Medicine, The General Hospital of the Western Theater Command, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study aimed to evaluate the sensitivity and heterogeneity of standard first-line chemotherapy regimens for colorectal cancer (CRC) using patient-derived tumor organoids (PDTOs). Drug sensitivity testing in 15 CRC PDTOs revealed varying proportions of samples classified as sensitive (inhibition rate > 50%) across different regimens: FOLFIRI (60%), FOLFOX (40%), CAPEOX (26.7%), and 5-Fluorouracil (26.7%). Furthermore, exploratory analysis indicated that for FOLFIRI and FOLFOX regimens, HER2(1+) status was significantly associated with lower inhibition grades compared to HER2(0) status (P < 0.05), implying a potential impact on the level of drug response. These findings demonstrate significant heterogeneity in the response of CRC PDTOs to first-line chemotherapies. Furthermore, at the organoid level, a low HER2 expression status may be associated with the heterogeneity of responses observed with specific drug regimens.
Keywords: colorectal cancer, patient derived tumor organoids, chemotherapy, drug sensitivity, HER2 heterogeneity
Received: 30 Apr 2025; Accepted: 26 May 2025.
Copyright: © 2025 Liu, Li, Li, Fu, Jia, Bai, Wu, Huang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fang Chen, Department of Clinical Laboratory, Second People's Hospital of Jiangyou, Mianyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.